Free tool
FAERS Monitor: Brineura
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761052 or its brand name (Brineura, Cerliponase Alfa). Reports on generic versions are filed under their own applications.
Reports
536
Serious
391
73% of reports
Hospitalization
196
Death reported
26
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia91
- seizure79
- vomiting38
- device related infection31
- device leakage28
- csf culture positive26
- pneumonia26
- headache22
- drug ineffective20
- off label use18
- device occlusion16
- general physical health deterioration16
- nausea16
- dystonia15
- disease progression14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 9 |
| 2018 | 29 |
| 2019 | 46 |
| 2020 | 52 |
| 2021 | 83 |
| 2022 | 84 |
| 2023 | 73 |
| 2024 | 52 |
| 2025 | 71 |
| 2026 | 37 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,623 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| csf culture positiveSignal | 26 | 12765.7 | 8268.7 | 240,918 |
| device related infectionSignal | 31 | 79.2 | 56.3 | 2,314 |
| device occlusionSignal | 16 | 44.7 | 27.6 | 640 |
| dystoniaSignal | 15 | 30.4 | 18.4 | 397 |
| seizureSignal | 79 | 26.9 | 21.9 | 1,950 |
| device leakageSignal | 28 | 25.4 | 17.7 | 632 |
| pyrexiaSignal | 91 | 10.3 | 8.6 | 769 |
| general physical health deteriorationSignal | 16 | 5.4 | 3.3 | 54 |
| disease progressionSignal | 14 | 4.6 | 2.8 | 37 |
| vomitingSignal | 38 | 3.2 | 2.3 | 56 |
| pneumoniaSignal | 26 | 3.2 | 2.2 | 37 |
| headache | 22 | 1.4 | 0.9 | 2 |
| off label use | 18 | 0.8 | 0.5 | 1 |
| nausea | 16 | 0.8 | 0.5 | 1 |
| drug ineffective | 20 | 0.6 | 0.4 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.